Liraglutide effects on beta‐cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes

Abstract

Liraglutide as add-on to metformin induces a clinically significant improvement in beta-cell function in overweight/obese, high cardiovascular risk patients with newly diagnosed well-controlled T2DM and CAD. The effect of liraglutide on DI is mediated entirely by improved AIRg whereas the effects on Si and Sg are neutral.

Effect of liraglutide on estimates of lipolysis and lipid oxidation in obese patients with stable coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial

“…We have previously reported that liraglutide reduced hyperglycemia and increased insulin response to glucose, doubling DI with no effect on insulin sensitivity (MINIMOD Millennium analysis) despite an expected loss in net body weight of 2.7 kg (Table ). The Boston Minimal Model of NEFA metabolim also involves additional glucometabolic parameters as compared to placebo.…”

“…*Excerpts of data published previously in Diabetes, Obesity and Metabolism (2017) and AIR g , DI and SI from MINMOD Millenium analysis …”

“…We found that the estimate of lipolysis (S ffa ) was not affected by metformin but, nevertheless, was suppressed during liraglutide therapy, although not significantly when corrected for placebo. Liraglutide is a powerful insulin secretagogue and NEFA nadir was significantly lower with liraglutide treatment and was attained earlier (Table ). Both lipolysis and lipid oxidation during the 180‐minute test were reduced by liraglutide‐metformin treatment but increased with placebo‐metformin (Figure S3).…”

“…Details concerning time course and intervention are presented online in Figure S1. At the beginning and end of each 12‐week treatment period, each treatment effect was evaluated by an im‐FSIGT using a standardized protocol according to the Boston Minimal Model (MINIMOD Millennium used for calculations) . An NEFA minimal model was applied to NEFA and glucose (Figure S2 and Table S1).…”

“…Two‐sided P < 0.05 was considered statistically significant. Power calculation was based on an improvement in disposition index (DI) greater than 70% and would require 22 patients in paired analyses to provide a statistical power of 80% . Details of post‐hoc power analysis are provided online in the supplementary appendix.…”